Kolon TissueGene Announces Topline Data from TG-C Phase 3 Knee Osteoarthritis Trial, Co-Primary Endpoints Not Met
Kolon TissueGene disclosed topline data from its Phase 3 clinical trial of TG-C for knee osteoarthritis.
The trial failed to meet both co-primary endpoints at 12 months: VAS pain score and WOMAC total score showed no statistically significant difference versus placebo.
Safety was consistent with previous studies, no new signals.
This failure may delay FDA discussions and commercialization plans, negatively impacting the stock price.
No shareholder return measures such as share buybacks or dividends were disclosed.
[AI Summary]The Phase 3 failure significantly impairs the value of Kolon TissueGene's core pipeline. Short-term downside pressure is expected, with future outcomes dependent on remaining trials and FDA dialogue.
KOSDAQ Filing Information
Major Management Matters Related To Investment Decision (Clinical Trial Results) (TGC 15302 Study Top-Line Data)